Eventide expands Biotech expertise with new analysts

published 29.07.2020 16:31

Image of article 'Eventide expands Biotech expertise with new analysts'

The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration.

Prior to joining Eventide, from 2017-2020, Dr. Ghosh was an Associate and subsequently a Vice President at Bain Capital for their Life Sciences Fund.

Ghosh and Chow support lead Portfolio Manager, Finny Kuruvilla, MD, PhD, on the Eventide Gilead Fund and the Eventide Healthcare & Life Sciences Fund.

BOSTON, July 29, 2020 /PRNewswire/ -- Eventide Asset Management, LLC, is pleased to welcome two new analysts to its portfolio team—Senior Research Analyst Joy Ghosh, Ph.D., and Associate Research Analyst Brian Chow, Ph.D.

The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration.

by Eventide Asset from prnewswire.com

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!